This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Steven J. Stryker, MD; Krystyna D. Kiel, MD; Alfred Rademaker, PhD; John M. Shaw, MD; Gerald T. Ujiki, MD; Stuart M. Poticha, MD

Arch Surg. 1996;131(5):514-519.

Abstract
Objective
To determine whether preoperative administration of combination chemotherapy and external beam irradiation ("chemoradiation") for patients with stage II or stage III rectal carcinoma had an impact on perioperative morbidity or oncologic outcome, as compared with patients not receiving preoperative chemoradiation.

Design
A group of patients with stage II or stage III rectal carcinoma receiving preoperative chemoradiation were followed up prospectively and compared in a nonrandomized fashion with an inception cohort group of similar patients.

Setting
Northwestern Memorial Hospital, Chicago, Ill, a tertiary care academic medical center.

Patients
Thirty patients with rectal carcinoma undergoing preoperative chemoradiation were compared with 56 patients not undergoing preoperative chemoradiation, and also with a subset group of 24 patients who received standard postoperative adjuvant chemoradiation.

Intervention
External beam radiation, 45 to 50 Gy, was delivered concurrently with fluorouracil and mitomycin 4 to 8 weeks prior to surgical resection.

Main Outcome Measures
Patients were followed up at regular intervals for either tumor recurrence or death. In addition, the group receiving preoperative chemoradiation was evaluated for major perioperative morbidity.

Results
All patients agreeing to preoperative chemoradiation completed therapy. Perioperative major morbidity in this group (13%) was comparable to previously published results. Of the 56 patients with stage II or stage III rectal carcinoma not receiving preoperative chemoradiation, only 24 (43%) completed standard postoperative adjuvant chemoradiation. Patients receiving preoperative chemoradiation (n=30), patients not receiving preoperative chemoradiation (n=56), and the subset of the group not receiving preoperative chemoradiation who completed standard postoperative chemoradiation (n=24) were followed up for a mean of 39 months, 31 months, and 32 months, respectively. Five-year actuarial local control rates were 96%, 83%, and 88%, respectively. Disease-free survival rates were 80%, 57%, and 47%, respectively. Overall survival rates were 85%, 48%, and 78%, respectively.

Conclusions
Preoperative chemoradiation in the treatment of stage II or stage III rectal carcinoma is well tolerated and not associated with an increase in subsequent perioperative major morbidity. In addition, local control, disease-free survival, and overall survival compare favorably with a nonrandomized inception cohort group of patients receiving standard postoperative adjuvant chemoradiation.

(Arch Surg. 1996;131:514-519)

Author Affiliations
From the Departments of Surgery (Drs Stryker, Ujiki, and Poticha), Radiation Oncology (Dr Kiel), Biometrics (Dr Rademaker), and Medicine (Dr Shaw), Northwestern University Medical School, Chicago, Ill.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rectal Cancer: MR Imaging before Neoadjuvant Chemotherapy and Radiation Therapy for Prediction of Tumor-Free Circumferential Resection Margins and Long-term Survival
Wieder et al.
Radiology 2007;243:744-751.
ABSTRACT | FULL TEXT  

Analysis of Early Postoperative Morbidity Among Patients with Rectal Cancer Treated with and without Neoadjuvant Chemoradiotherapy
Valenti et al.
Ann. Surg. Oncol. 2007;14:1744-1751.
ABSTRACT | FULL TEXT  

Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation
Calvo et al.
Ann Oncol 2006;17:1103-1110.
ABSTRACT | FULL TEXT  

Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901
Ryan et al.
JCO 2006;24:2557-2562.
ABSTRACT | FULL TEXT  

Impact of Preoperative Staging and Chemoradiation Versus Postoperative Chemoradiation on Outcome in Patients With Rectal Cancer: A Decision Analysis
Telford et al.
JNCI J Natl Cancer Inst 2004;96:191-201.
ABSTRACT | FULL TEXT  

Preoperative Chemoradiation in Patients With Resectable Rectal Cancer: Results on Tumor Response
Bozzetti et al.
Ann. Surg. Oncol. 2002;9:444-449.
ABSTRACT | FULL TEXT  

Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival
Onaitis et al.
Ann. Surg. Oncol. 2001;8:801-806.
ABSTRACT | FULL TEXT  

Distal Margin Requirements After Preoperative Chemoradiotherapy for Distal Rectal Carcinomas: Are <= 1 cm Distal Margins Sufficient?
Kuvshinoff et al.
Ann. Surg. Oncol. 2001;8:163-169.
ABSTRACT | FULL TEXT